Equity Profile

RVMD

Revolution Medicines, Inc.

Health CareBiotechnology$31.7B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenues.

N/A

Revenue

While specific revenue estimates are not available, any revenue figures provided will indicate the company's market traction and effectiveness in commercializing its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RVMD Q2-2026 Earnings Preview

Context

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for cancer. With a market cap of $32 billion, it plays a significant role in the healthcare sector, particularly in the fight against various forms of cancer through innovative drug development.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-0.14%

Last Quarter Recap

In Q1 2026, Revolution Medicines reported an EPS of -$2.29, missing estimates by nearly 25%. The stock reacted positively the following day, gaining 2.62%.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, especially given the company's focus on innovative cancer therapies. However, the recent history of earnings misses raises concerns.

Bull Case

If the company can demonstrate improved cost management and potentially better-than-expected clinical trial results, it could lead to a significant positive reaction in the stock.

Bear Case

Conversely, if the company reports another earnings miss or fails to provide clear guidance on future revenue, it could lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific steps is the company taking to improve its EPS moving forward?

Given the recent history of earnings misses, investors will be looking for concrete plans that could lead to improved financial performance.

Will there be any updates on clinical trials or product pipeline that could impact future revenues?

Updates on the pipeline can significantly influence investor sentiment and expectations for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Revolution Medicines to turn around its financial performance, especially if there are positive updates on clinical trials.

Supporting Evidence

The stock has historically reacted positively to any signs of improvement in clinical trial results.

Options are pricing in a larger move than the stock has typically experienced, indicating a potential overreaction to past earnings misses.

Key Risk

If the company can show a clear path to profitability or significant advancements in its drug pipeline, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to manage costs and provide updates on its product pipeline, which are critical for future growth.

Bull Confirmed If

A reduction in EPS loss to below -$1.50 would indicate improved financial health and operational efficiency.

Bear Confirmed If

An EPS loss greater than -$2.50 would confirm ongoing financial struggles and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±7.42%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±7.4% while RVMD has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

51.3%

Calls (25K)P/C Ratio: 0.45Puts (37K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$18.0M

120,000 sh

1 insider

Net

$18.0M

Net selling

Most Active Insiders· 1 open-market trade

See RemarksGOLDSMITH MARK A
$18.0M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If the company beats expectations, history suggests a potential stock increase of around 2.45%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with historical patterns suggesting an average drop of around 0.14%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial results that could impact future revenue.
2Details on cost management strategies and their expected impact on EPS.
3Guidance on the product pipeline and anticipated timelines for new therapies.
4Management's outlook on market conditions and competition in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for cancer....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenues.

N/A

Revenue

While specific revenue estimates are not available, any revenue figures provided will indicate the company's market traction and effectiveness in commercializing its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RVMD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-12.50%

Avg Stock Reaction

-0.14%

Last Quarter Recap

In Q1 2026, Revolution Medicines reported an EPS of -$2.29, missing estimates by nearly 25%. The stock reacted positively the following day, gaining 2.62%.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, especially given the company's focus on innovative cancer therapies. However, the recent history of earnings misses raises concerns.

Bull Case

If the company can demonstrate improved cost management and potentially better-than-expected clinical trial results, it could lead to a significant positive reaction in the stock.

Bear Case

Conversely, if the company reports another earnings miss or fails to provide clear guidance on future revenue, it could lead to a negative reaction from investors.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific steps is the company taking to improve its EPS moving forward?

Given the recent history of earnings misses, investors will be looking for concrete plans that could lead to improved financial performance.

Will there be any updates on clinical trials or product pipeline that could impact future revenues?

Updates on the pipeline can significantly influence investor sentiment and expectations for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Revolution Medicines to turn around its financial performance, especially if there are positive updates on clinical trials.

Supporting Evidence

The stock has historically reacted positively to any signs of improvement in clinical trial results.

Options are pricing in a larger move than the stock has typically experienced, indicating a potential overreaction to past earnings misses.

Key Risk

If the company can show a clear path to profitability or significant advancements in its drug pipeline, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to manage costs and provide updates on its product pipeline, which are critical for future growth.

Bull Confirmed If

A reduction in EPS loss to below -$1.50 would indicate improved financial health and operational efficiency.

Bear Confirmed If

An EPS loss greater than -$2.50 would confirm ongoing financial struggles and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±7.42%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±7.4% while RVMD has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

51.3%

Calls (25K)P/C Ratio: 0.45Puts (37K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$18.0M

120,000 sh

1 insider

Net

$18.0M

Net selling

Most Active Insiders· 1 open-market trade

See RemarksGOLDSMITH MARK A
$18.0M
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If the company beats expectations, history suggests a potential stock increase of around 2.45%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with historical patterns suggesting an average drop of around 0.14%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on clinical trial results that could impact future revenue.
2Details on cost management strategies and their expected impact on EPS.
3Guidance on the product pipeline and anticipated timelines for new therapies.
4Management's outlook on market conditions and competition in the biotechnology sector.